How obesity affects immune function is not well understood. Clinically, obesity is strongly associated with severe TH2 immunopathology 1-3 , though the physiological, cellular, and molecular underpinnings of this association remain obscure. Here, we demonstrate that obese mice are susceptible to severe atopic dermatitis (AD), a major manifestation of TH2 immunopathology and disease burden in humans 4,5 . Mechanistically, we show that dysregulation of the nuclear hormone receptor (NHR) PPAR! (peroxisome proliferator-activated receptor gamma) in T cells is a causal link between obesity and the increased TH2 immunopathology. We find that PPAR! oversees a cellular metabolic transcriptional program that restrains nuclear gene expression of the chief TH2 priming and effector cytokine interleukin-4 (IL-4). Accordingly, thiazolidinediones (TZDs), potent PPAR! agonists, robustly protect obese mice from TH2 immunopathology. Collectively, these findings establish PPAR! as a molecular link between obesity and TH2 immune homeostasis and identify TZDs as novel therapeutic candidates for TH2 immunopathology.
immunopathology. Recent epidemiological and clinical studies have uncovered associations between obesity and AD, a prominently TH2-driven immunopathology in humans 2, 9 , and the striking co-increase in worldwide incidence of obesity and AD, suggest the two seemingly independent disease entities may be related 6, 8, 10 . To assess the relationship between obesity and AD, we challenged obese mice fed high-fat diet (HFD) with a well-characterized experimental model of MC903-induced AD on the ear 11, 12 ( Figure 1a ). Strikingly, the HFD mice, compared to control lean mice, displayed an overall increased inflammatory response, as measured grossly by a ~3-fold increase in change in ear thickness (Figure 1b ). Consistently, physical examination of the MC903-treated ears revealed prominent erythema and scale which was increased in the HFD mice, hallmarks of dermal inflammation (Figure 1c ). Under histological evaluation, the obese mice exhibited increased epidermal acanthosis, hyperkeratosis, and spongiosis, hallmark characteristics of human AD. Impressively, the dermis was significantly expanded with leukocytic inflammation (dashed line), which was relatively diminished in the lean mice ( Figure 1d ).
Since atopic disease is classically driven by TH2 immunity [13] [14] [15] , we sought to further characterize the infiltrating T cells induced by our experimental model of AD. Flow cytometric analyses revealed that the CD4 + conventional T cell (Tconv), regulatory T cell (Treg), and CD8 + T cell populations were all increased in the obese mice ( Figure 1e) ; however, the Tconv cells were the predominant T cell population and were significantly increased in their IL-4-competent (~8.2 fold increase) but not IFN!-competent populations compared to the lean mice (Figure 1f) , an indicator of an increased TH2-polarized response. Of note, the link between obesity and TH2 immunopathology is dose-dependent as mice fed short-term HFD also display an increased inflammatory response upon induction of experimental AD, though to a lesser extent compared to the conventional HFD obese mice (Extended Data Figure 1a -f).
Nuclear hormone receptors (NHRs) are sensors of shifting physiological states 16, 17 , and we wondered how NHRs were expressed in different types of TH subsets and if any NHRs were specifically upregulated in TH2 cells. We surveyed the expression of NHRs in in vitro differentiated TH1, TH2, and TH17 cells and identified Pparg (and its heterodimeric partner Rxra) as highly and differentially expressed in TH2 cells (Extended Data Figure 2a ). Further focused validation evaluating end-point and time-course gene expression as well as protein expression clearly identified PPAR! as differentially and highly expressed in TH2 cells (Extended Data Figure 2b-d) . Further, a differential analysis of genes involved in transcriptional regulation across in vitro differentiated TH1, TH2, and TH17 cells revealed Pparg expression to be highly specific to TH2 cells (Extended Data Figure 2e .) Consistent with our experiments, PPAR! has recently been demonstrated as a transcription factor important for regulating transcriptional networks in TH2 cells, though its physiological relevance and functional importance is not well understood [18] [19] [20] . PPAR! and its ligands are master regulators of adipogenesis 21-24 . It is highly expressed in adipocytes and several other cell types (including immune cells such as fatresident Treg cells 25,26 ) found within adipose tissue. Since obesity-associated dysregulation of PPAR! activity in adipose tissue is an established cause of adipose tissue insulin resistance, we hypothesized that PPAR! may be expressed in vivo in TH2 cells and similarly undergo obesity-associated dysregulation to promote a maladaptive TH2 immune responses in obese mice 22, 24, 27 . Indeed, by sorting on the infiltrating CD4 + Tconv and Treg cells of lean mice, we were able to detect an appreciable 2-fold increase in These results suggest that HFD-induced obesity is largely epistatic to T cell-specific genetic deficiency of Pparg in controlling TH2 immune homeostasis, linking the obesityassociated susceptibility to TH2 immunopathology with dysregulation of PPAR! in T cells.
Our in vivo studies revealed PPAR! as a T cell-intrinsic restraint on TH2 immune responses. Although the transcriptomic and cistromic biology of PPAR! has been studied extensively in the context of macrophages and dendritic cells 28-31 , the genomic regulation of PPAR! in T cells is less studied. Intriguingly, a recent study utilizing genome-wide CRISPR knock-out screens included PPAR! as part of the core transcriptional factors regulating TH2 activation and identity 20 ; however, the functional role of PPAR! activation or deficiency on TH2 cells has not been advanced. To gain mechanistic insights into how PPAR! may be regulating TH2 immune responses and restraining TH2-driven immunopathology, we conducted transcriptomic analyses of in vitro differentiated TH2 cells from wild-type or PPAR! TKO mice with or without treatment with the PPAR!-agonist rosiglitazone (Rosi) to experimentally activate the PPAR! transcriptional program. 1071 genes were differentially expressed, and hierarchical clustering revealed clear clusters of Rosi-responsive genes that were dependent on PPAR! -the Rosi Up Cluster (455 genes) and Rosi Down Clusters I (171 genes) and II (361 genes) ( Figure 3a ). To complement transcriptomic analyses, we empirically identified the DNA binding sites for PPAR! in TH2 cells via ChIP-Seq. The top DNA-binding motif discovered was the canonical PPARresponse element (PPRE, Figure 3b .) 2534 binding sites mapping to 1563 genes were identified, of which 215 genes were members of the Rosi Up or Down I and II clusters ( Figure 3c ). Unexpectedly, ontological analyses of these 215 genes identified only one consensus GO term: response to organic cyclic compounds -a parent term for a large group of metabolism-related ontologies (Figure 3d ). In contrast, when similar analyses were applied to the entirety of the genes found in the Rosi Up and Rosi Down clusters, the ontologies were exclusively immunological for the Rosi Down Clusters and a mix of metabolic and immunological for the Rosi Up Cluster (Figure 3d ). Taken together, this suggests that PPAR! activation directly activates genes involved in cellular metabolism whose collective expression and function then alters the expression of the genes associated with immunological processes. Congruent with this model, several metabolism genes markedly induced by Rosi treatment exhibited high PPAR! ChIP peak scores, whereas several key immunological genes induced by Rosi treatment had largely diminished or absent PPAR! ChIP peak scores ( Figure 3e ). Importantly, Il4, the chief TH2 priming and effector cytokine, was found in the Rosi Down II Cluster and had an absent PPAR! ChIP peak score (Figure 3f Metabolic regulation of immune function occurs in a highly context and cell-type specific manner 32-34 . To further understand the mechanism by which PPAR!-activated metabolic reprogramming could control immunological function in TH2 cells, we examined genes in the Rosi Up Cluster that were also direct targets of PPAR!. We found genes whose consensus activities would promote de novo lipogenesis (Plin2, Gpam, Dgat1), fatty acid oxidation (Pdk4, Cpt1a, Acaa2, Eci2, Slc25a20, Acadl, Acsl5), and mitochondrial mass (Etfb, Mrpl45, Mrpl1), which would likely manifest in mitochondrial substrate usage of fatty acids (Extended Data Figure 4d Collectively, these studies argue for PPAR! as a core TH2 transcription factor enforcing mitochondrial oxidative capacity required to restrain over-exuberant TH2 effector function.
Due to the robust ability of Rosi to decrease TH2 effector function and enforce lipid catabolic pathways in a PPAR!-dependent fashion in vitro, we hypothesized that perhaps Rosi treatment could be used to protect obese mice from exacerbated AD. Remarkably, mice treated with Rosi had substantially reduced disease, as measured by a ~40% reduction in increase in ear thickness (Figure 4a Taken together, our studies provide a physiological, cellular, and molecular basis for the clinically observed association between obesity and TH2 immunopathology, establishing obesity-associated dysregulation of PPARg in T cells as an important driver of obesity-associated TH2 immunopathology. Leveraging mouse genetics, we identify loss-of-function of PPARg specifically in T cells as a key mechanistic step in the potentiation of TH2 immunopathology in the obese state. Unexpectedly, we find that PPARg serves as a brake on effector function by controlling mitochondrial metabolism.
Further, we demonstrate that the PPARg agonists, TZDs, commonly prescribed as insulinsensitizers for treatment of Type-2 diabetes, could be used to treat TH2 immunopathology, a novel indication. Fundamentally, we demonstrate that distinct physiological metabolic states can alter cellular metabolic states to shape immune responses in specific ways to modulate disease susceptibility. ChIP-Seq library generation. Naïve CD4 + T cells were activated and polarized in TH2 conditions.
Nobs
On day 1 and 2, T cells were transduced with a retroviral vector expressing TY1-tagged Pparg.
On day 4, transduced T cells were harvested for ChIP as described previously 4 utilizing a TY1 antibody (Sigma, SAB4800032). ChIP-sequencing libraries were constructed and sequenced (50 bp single end reads) as described previously 4 . Short DNA reads were demultiplexed using Illumina CASAVA v1.8.2. Reads were aligned against the mouse mm10 reference genome using the Bowtie2 aligner with standard parameters that allow up to 2 mismatches per read. Peak calling, motif analyses, and other data analysis were performed using HOMER, a software suite for ChIP-seq analysis as described previously 4 . Visualization of ChIP-Seq results was achieved by uploading custom tracks onto the UCSC genome browser. Cells were incubated for 30 min in 37 °C incubator, and then treated with 50 µL/well of loading buffer (0.5mM 2-DG (2-Deoxy-D-glucose) and 0.5Ci (3H-2DG)). Negative control wells were additionally treated with 10 µL/well of 1.5 mM cytochalasin B in DMSO to suppress active glucose uptake and control for non-specific uptake and binding of 3 H-2-DG. Cells were incubated for 1 hour at 37 °C and then washed three times with PBS. Cells were lysed in 300 µL of 0.1 N NaOH.
RNA-Seq library generation and sequencing analysis.
200 µL of cell lysis/sample were collected for radioactivity measurements via scintillation counter.
The remaining amount was utilized to conduct the Bradford assay to quantify protein concentration. All radioactivity counts were normalized to sample protein concentration, and the negative control counts were further subtracted from experimental sample measurements. 
